ObsEva SA (OBSV)

[Pan_O_War]

Repost: From a financial perspective, the Company has a relatively good cash runway (Current Ratio: 4, Cash Ratio: 3) with limited debt obligations. That said-the Company burn rate is rather high with no revenue yet on its product lines. The hope/expectation here is that Linzagolix will receive approval both in EU and US, respectively (uterine fibroids) to lead a strong product pipeline through 2022. The Company was able to sign an agreement with Syneos Health to broadly commercialize their product, established a
$135MILS

borrowing agreement with JGB Management to retire current debt and fund future programs. Notes paid in stock at $3.20 price and Warrants with $3.65 strike. They also negotiated more favorable terms on sales milestones and royalty payments to Kissei on Linzagolix. The Company is positioning itself for US and/or EU approval upcoming, and the broad commercialization of their front-running product. Federal (US/EU) approval of Linzagolix will send this stock IMO.